Orthotopic osteosarcoma and lung metastasis mouse model and its preparation and application

By injecting the composition of Matrigel and osteosarcoma cells into the tibial marrow cavity of mice, an in situ and lung metastasis model was formed, which solved the problems of long latency and poor stability of the osteosarcoma model in the prior art, and achieved rapid and high-stage Present osteosarcoma and lung metastasis models, suitable for research and drug screening.

CN115836666BActive Publication Date: 2024-11-01LONGHUA HOSPITAL SHANGHAI UNIV OF TRADITIONAL CHINESE MEDICINE
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202111102591.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-09-20
Publication Date
2024-11-01
Estimated Expiration
2041-09-20

AI Technical Summary

Technical Problem

The existing animal models of osteosarcoma have problems such as long latency, poor stability and large experimental errors in simulating pathological progression and lung metastasis in human clinical osteosarcoma, and it is difficult to quickly and effectively simulate pathological progression and metastasis of human clinical osteosarcoma.

Method used

Using a modeling composition containing Matrigel and osteosarcoma cells, cells are injected into the marrow cavity of the mouse tibial marrow through a microsyringe to form osteosarcoma in situ and form lung metastases in the lungs, using specific cell lines such as 143B cells and Labeled proteins such as luciferase are tracked to control injection volume and cell concentration to ensure rapid formation and high reproducibility.

Benefits of technology

The rapid formation of in situ osteosarcoma and lung metastasis models has been achieved, with short incubation period, fast growth, high reproducibility and sensitive lesion monitoring, which is suitable for studying osteosarcoma lesions and lung metastasis mechanisms and drug screening.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN115836666B_ABST
    Figure CN115836666B_ABST
Patent Text Reader

Abstract

The present invention provides an in situ osteosarcoma and lung metastasis mouse model and its preparation method and application. Specifically, the present invention provides a method for preparing a mouse model of osteosarcoma and lung metastasis, comprising the following steps: (a) providing an injectable modeling composition, the volume of the modeling composition is 8-15 microliters, and the modeling composition is a suspension containing Matrigel and osteosarcoma cells; and (b) applying the injectable modeling composition to the tibia of mice to form a mouse model of osteosarcoma and lung metastasis. The mouse model of the present invention is an ideal model for exploring the role and mechanism of specific factors in the pathological process of osteosarcoma, and is also an ideal tool for studying lung metastasis, tumor microenvironment and evaluating the therapeutic effect in vivo.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of tumor models, and in particular to orthotopic osteosarcoma and lung metastasis mouse models and preparation methods and applications thereof. Background Art

[0002] Osteosarcoma is the most common primary bone cancer in children and adolescents [1,2] While infiltrating surrounding tissues, metastasis to distant organs such as the lungs may occur.

[0003] Lung metastasis is a major challenge in the treatment of osteosarcoma. Although the 5-year survival rate of patients with primary osteosarcoma has increased to 70%, the 5-year survival rate of patients with lung metastasis is still as low as 20-30%. [3-5] .

[0004] Since 1970, due to the application of chemotherapy, the overall survival rate of osteosarcoma patients has increased to about 70%, but there has been no increase or improvement in the past 30 years.

[0005] Osteosarcoma animal models can be produced by spontaneous, induced, genetically engineered, or transplanted techniques; the most commonly used animals are mice, dogs, and zebrafish. [6,7] Spontaneous osteosarcoma models are rarely used due to factors such as long tumor formation time, inconsistent tumor incidence, low morbidity, and poor stability. [8,9] Although induced osteosarcoma models are easier to obtain than spontaneous osteosarcoma, the application of induced osteosarcoma models is limited because the induction factors can affect the microenvironment, pathogenesis, and pathological characteristics of osteosarcoma.

[10] .

[0006] Transgenic models can better simulate the physiological and pathological environment of the human body and help understand the pathogenesis of cancer. However, due to the difficulty, time and cost of genetic modification, transgenic animal models also have their own limitations. In addition, even in the most widely accepted transgenic animal model produced by p53 and Rb gene modification, only about 16.3% of sarcomas occur in the bones of the limbs. [11,12] .

[0007] Tumor transplantation has the advantages of simple operation, stable tumor formation rate, and good homogeneity. It is one of the most commonly used methods for making primary lesions and distant metastatic cancer models in recent years. According to the transplantation site, it can be divided into heterotopic transplantation and orthotopic transplantation. Heterotopic transplantation of osteosarcoma is the injection of osteosarcoma cells into the primary osteosarcoma site (bone) of the animal, usually by subcutaneous transplantation.

[13] Although heterotopic transplantation is simple and does not require surgical intervention in animals, the site of subcutaneous injection of osteosarcoma cells cannot represent the true human osteosarcoma microenvironment. Orthotopic transplantation of osteosarcoma is the injection of osteosarcoma cells into the bones of animals. Compared with heterotopic transplanted tumors, orthotopic transplanted osteosarcoma has the characteristics of short latency, fast growth, and strong erosion, making it an ideal animal model for osteosarcoma-related research.

[0008] However, the existing orthotopic transplanted osteosarcoma models require a long time (usually about 8 weeks or longer) to observe the orthotopic osteosarcoma and metastatic lesions, and there are great differences between different batches or different animal models in the same batch, which limits the application of this model in experimental research and easily leads to experimental errors and even wrong experimental conclusions.

[0009] Therefore, in order to gain a deeper understanding of the basic mechanisms of osteosarcoma lesions and lung metastasis and to develop new therapeutic strategies, there is an urgent need to develop animal models that can rapidly and effectively simulate the pathological progression and metastasis of human clinical osteosarcoma. Summary of the invention

[0010] The purpose of the present invention is to provide an animal model that can quickly and effectively simulate the pathological progression and metastasis of human clinical osteosarcoma, and its preparation method and application.

[0011] In a first aspect of the present invention, a method for preparing a mouse animal model of osteosarcoma and lung metastasis is provided, comprising the following steps:

[0012] (a) providing an injectable modeling composition, wherein the volume of the modeling composition is 8-15 μl, and the modeling composition is a suspension containing Matrigel (matrigel) and osteosarcoma cells, wherein the total number of human osteosarcoma cells in the modeling composition is 1×10 5 Up to 3×10 5 ;and

[0013] (b) administering the injectable modeling composition to mice, thereby forming a mouse animal model of osteosarcoma and lung metastasis.

[0014] In another preferred embodiment, the modeling composition is formed by resuspending osteosarcoma cell precipitates obtained by centrifugation using Matrigel.

[0015] In another preferred embodiment, the modeling composition does not contain or substantially does not contain a culture medium (such as a culture medium for culturing osteosarcoma cells).

[0016] In another preferred embodiment, in the modeling composition, the content of the culture medium is ≤20 volume %, preferably ≤10 volume %, more preferably ≤5 volume % or 0 volume %, based on the total volume of the modeling composition.

[0017] In another preferred embodiment, the volume of the injection composition is 8-15 μl, preferably 9-12 μl, and more preferably ≤10 μl, such as 9-11 μl or 10 μl.

[0018] In another preferred embodiment, the concentration of human osteosarcoma cells in the injection composition is 1×10 4 Up to 3×10 4 / μl, preferably 1.5×10 5 Up to 2.5×10 4 / microliter, more preferably 1.8×10 4 to 2.2×10 4 / μl.

[0019] In another preferred embodiment, the number of human osteosarcoma cells in the injection composition is 1×10 5 Up to 3×10 5 , preferably 1.5×10 5 Up to 2.5×10 5 , more preferably 1.8×10 5 to 2.2×10 5 .

[0020] In another preferred embodiment, the osteosarcoma cells include primary osteosarcoma cells and passaged osteosarcoma cells.

[0021] In another preferred embodiment, the osteosarcoma cells are selected from the following group: 143B cells, MNNG cells, MG-63 cells, U-2OS cells, or a combination thereof.

[0022] In another preferred embodiment, the osteosarcoma cells are not genetically engineered.

[0023] In another preferred embodiment, the osteosarcoma cells are genetically engineered.

[0024] In another preferred embodiment, the osteosarcoma cells express exogenous marker proteins that can be used for detection.

[0025] In another preferred embodiment, the marker protein is selected from the following group: luciferase, green fluorescent protein (GFP), red fluorescent protein (RFP), yellow fluorescent protein (YFP), or a combination thereof.

[0026] In another preferred embodiment, the osteosarcoma cells are 143B cells expressing luciferase and / or 143B cells expressing GFP.

[0027] In another preferred example, in the injectable composition for modeling, the concentration of the Matrigel matrix component is in the range of about 6-15 mg / ml, preferably 8-12 mg / ml.

[0028] In another preferred embodiment, the mouse animal model of osteosarcoma and lung metastasis has one or more characteristics selected from the following group:

[0029] (c1) Osteosarcoma in situ in the tibia more than 2 weeks after modeling (e.g., 2-6 weeks);

[0030] (c2) osteosarcoma with lung metastasis in the lungs more than 3 weeks after modeling (e.g., 3-6 weeks);

[0031] (c3) At 4 weeks after modeling, the volume of the osteosarcoma in situ in the tibia was ≥500 mm 3 , preferably ≥600mm 3 , preferably ≥700mm 3 ;

[0032] (c4) At 5 weeks after modeling, the volume of the osteosarcoma in situ in the tibia was ≥800 mm 3 , preferably 900mm 3 , preferably ≥1000mm 3 ;

[0033] (c5) Six weeks after modeling, the volume of the osteosarcoma in situ in the tibia was ≥1000mm 3 , preferably 1100mm 3 , preferably ≥1200mm 3 .

[0034] In another preferred embodiment, the mouse is an immunodeficient nude mouse.

[0035] In another preferred embodiment, in the method, osteosarcoma cells from a culture system (such as a culture dish) are divided into n injectable modeling compositions, and are respectively administered to n mice in a batch, wherein n is a positive integer ≥6.

[0036] In another preferred embodiment, n is 8-15 (i.e., 8, 9, 10, 11, 12, 13, 14, 15), more preferably 9-12.

[0037] In the second aspect of the present invention, there is provided a use of a mouse animal model of osteosarcoma and lung metastasis prepared by the method described in the first aspect of the present invention, wherein the model is used as an animal model for studying the pathogenesis of human osteosarcoma, or as an animal model for screening potential drugs for treating human osteosarcoma.

[0038] In another preferred embodiment, the pathogenesis of human osteosarcoma includes: the mechanism of osteosarcoma growth in situ and the mechanism of lung metastasis.

[0039] In another preferred embodiment, the potential drug inhibits the growth of osteosarcoma in situ and inhibits the lung metastasis of osteosarcoma.

[0040] In a third aspect of the present invention, a method for screening or identifying a potential therapeutic agent for treating or alleviating osteosarcoma and its related lung metastasis is provided, comprising the following steps:

[0041] (a) in a test group, in the presence of a test compound, administering the test compound to a mouse animal model prepared by the method of the first aspect of the present invention, analyzing the osteosarcoma lesions in the tibia and / or the osteosarcoma lesions of lung metastasis in the animal model of the test group, and in a control group in which the test compound is not administered and other conditions are the same, analyzing the osteosarcoma lesions in the tibia and / or the osteosarcoma lesions of lung metastasis in the animal model of the control group;

[0042] (b) comparing the lesions of the test group and the control group animal models, wherein, if the lesions in the animal model administered with the test compound are improved compared with the control group, it indicates that the test compound can be used as a potential therapeutic agent for osteosarcoma and its related lung metastasis.

[0043] In another preferred embodiment, the method is non-diagnostic and non-therapeutic.

[0044] In another preferred embodiment, the method further comprises the step of killing the model animal.

[0045] In another preferred embodiment, the improvement is a statistically significant improvement.

[0046] In another preferred embodiment, starting from the second week after modeling, the osteosarcoma lesions in the tibia of the test group and the control group animal models are analyzed and compared.

[0047] In another preferred example, starting from the third week after modeling, the osteosarcoma lesions in the lung metastases of the test group and the control group animal models are analyzed and compared.

[0048] In another preferred embodiment, the analysis includes: observation and analysis by a luciferase-based in vivo imaging system.

[0049] In another preferred embodiment, the analysis includes: obtaining a cell or tissue sample from the mouse model animal and performing analysis.

[0050] In another preferred embodiment, the cells or tissues include osteosarcoma cells or tissues metastasized to the lung.

[0051] In a fourth aspect of the present invention, a mouse animal model of osteosarcoma and lung metastasis is provided, wherein the mouse animal model is prepared by the method described in the first aspect of the present invention.

[0052] In a fifth aspect of the present invention, a kit for preparing a mouse animal model of osteosarcoma and lung metastasis is provided, the kit comprising:

[0053] (Z1) an injectable modeling composition, wherein the volume of the modeling composition is 8-15 μl, and the modeling composition is a suspension containing Matrigel and osteosarcoma cells, wherein the total number of human osteosarcoma cells in the modeling composition is 1×10 5 Up to 3×10 5 ;

[0054] (Z2) a microsyringe, wherein the microsyringe is configured to administer 8-15 microliters of the injectable modeling composition to the tibia of a mouse;

[0055] (Z3) a 1 ml graduated syringe, wherein the 1 ml graduated syringe is configured to form a modeling microhole on the tibia of the mouse, wherein the modeling microhole is suitable for the microsyringe to perform modeling injection;

[0056] (Z4) Optional luciferase substrate.

[0057] In the sixth aspect of the present invention, there is provided a use of the kit according to the fifth aspect of the present invention, which is used to prepare a test kit for preparing a mouse animal model of osteosarcoma and lung metastasis.

[0058] In the seventh aspect of the present invention, an isolated osteosarcoma cell or tissue sample with lung metastasis is provided, wherein the osteosarcoma cell or tissue sample with lung metastasis is derived from a mouse animal model of osteosarcoma and lung metastasis prepared by the method described in the first aspect of the present invention.

[0059] In another preferred embodiment, the lung metastatic cells or tissues are derived from the mouse animal model 3 or 4 weeks after modeling.

[0060] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS

[0061] Figure 1 The surgical tools used in one embodiment of the present invention are shown. A. 1 ml graduated syringe. B. Micro syringe.

[0062] Figure 2Visualization of the intratibial injection procedure in one embodiment is shown. A. Tibial intramedullary injection site in an immunodeficient nude mouse. B. A 1 ml sterile syringe with a needle is percutaneously drilled through the proximal tibial plateau (top of the tibia) and inserted into the tibial intramedullary cavity. C. Side view of the drilling process. The syringe needle is parallel to the long axis of the tibia (solid line). D. Tibial intramedullary injection using a microsyringe filled with osteosarcoma cells.

[0063] Figure 3 The visualization of mouse osteosarcoma growth in one embodiment of the present invention is shown. A. Mouse orthotopic osteosarcoma model was successfully established. B. Isolated orthotopic osteosarcoma. C. Tumor volume was measured with a vernier caliper, and the calculation formula is as follows: tumor volume = 0.5 × longest diameter × shortest diameter × shortest diameter. D. X-ray photos of the same mouse at different times (1 to 6 weeks). E. Images obtained 4 weeks after luciferase-labeled 143B cells were injected into the mouse tibia, showing the fluorescence intensity of orthotopic (primary) osteosarcoma.

[0064] Figure 4 Figure 1 shows the osteosarcoma lung metastasis in one embodiment of the present invention. A. The image obtained 4 weeks after luciferase-labeled 143B cells were injected into the tibial bone marrow cavity of mice shows the fluorescence intensity of the lung metastasis. B. Osteosarcoma lung metastasis in isolated lung, red arrows indicate osteosarcoma lung metastasis clones (×20). CH&E staining shows osteosarcoma lung metastasis in lung tissue (scale bar is 200 μm).

[0065] Figure 5 The figure shows the osteosarcoma lung metastasis in one embodiment of the present invention. The osteosarcoma lung metastasis is modeled by using GFP-labeled 143B cells. A is a picture of a paraffin-embedded section of an in situ osteosarcoma specimen obtained under a microscope; B shows a picture of an entire osteosarcoma lung metastasis specimen obtained under a fluorescence microscope. DETAILED DESCRIPTION

[0066] After extensive and in-depth research, the inventors have developed a new in situ osteosarcoma and lung metastasis mouse model for the first time through a large number of screening and optimization. This mouse model can not only simulate the pathological progression and metastasis characteristics of human clinical osteosarcoma, but also has many advantages such as high reproducibility, short modeling time, and obvious lung metastasis. Specifically, the inventors use a trace amount of specific human osteosarcoma cells, combined with a specific injection formula and injection method, so that an in situ osteosarcoma can be quickly formed in the tibial medullary cavity and an osteosarcoma lung metastasis lesion can be formed in the lungs, thereby simulating the pathological progression and metastasis of human clinical osteosarcoma as much as possible, providing a new tool for studying the basic mechanism of osteosarcoma lesions and lung metastasis, and providing a useful tool for the development of drugs for treating osteosarcoma and osteosarcoma-related lung metastasis. The present invention was completed on this basis.

[0067] Animal models and methods for their construction

[0068] As used herein, the terms "animal model of the present invention", "osteosarcoma and lung metastasis mouse model of the present invention", "mouse model of the present invention", and "mouse animal model of the present invention" are used interchangeably and refer to a mouse animal model constructed using the method of the present invention that has both in situ osteosarcoma lesions and osteosarcoma lesions with lung metastases.

[0069] Typically, the mouse model of the present invention can adopt the optimized method of the present invention, and a specific number of human osteosarcoma cells (especially 143B cells, MNNG cells, etc.) can be injected into the tibial bone marrow cavity of mice in a batch in a specific formula, thereby forming a microenvironment that is conducive to the colonization and growth of osteosarcoma cells, thereby quickly forming in situ osteosarcoma lesions and pulmonary metastatic osteosarcoma lesions.

[0070] In a preferred embodiment, the method for constructing the animal model comprises the following steps: after the mouse is anesthetized by inhaling a constant flow of 2% isoflurane and 98% oxygen, 10 μl of 2×10 5 Matrigel containing 143B osteosarcoma cells was injected into the tibial medullary cavity of immunodeficient nude mice. When the primary osteosarcoma grew to the maximum tumor size allowed in the IACUC-approved protocol, the mice were killed by cervical dislocation after CO2 inhalation and disinfected with 75% alcohol, and then the osteosarcoma-involved tibia, femur and lung were dissected with sterile scissors and fixed with 4% paraformaldehyde for 24 h.

[0071] Typically, the mouse animal model of orthotopic osteosarcoma and lung metastasis of the present invention has one or more (or all) characteristics selected from the following groups:

[0072] (c1) Osteosarcoma in situ is formed in the tibia more than 2 weeks after modeling (e.g., 2-6 weeks);

[0073] (c2) osteosarcoma with lung metastasis formed in the lungs more than 3 weeks after modeling (e.g., 3-6 weeks);

[0074] (c3) At 4 weeks after modeling, the volume of the osteosarcoma in situ in the tibia was ≥500 mm 3 , preferably ≥600mm 3 , preferably ≥700mm 3 .

[0075] (c4) At 5 weeks after modeling, the volume of the osteosarcoma in situ in the tibia was ≥800 mm 3 , preferably 900mm 3 , preferably ≥1000mm 3 ;

[0076] (c5) Six weeks after modeling, the volume of the osteosarcoma in situ in the tibia was ≥1000mm 3 , preferably 1100mm 3 , preferably ≥1200mm 3 .

[0077] In the method of the present invention, in order to successfully establish a mouse model of osteosarcoma and lung metastasis, the volume of the modeling composition should be limited. In the present invention, preferably, the volume of the injection composition is 8-15 microliters, preferably 9-12 microliters, and more preferably 10 microliters. The inventor's research shows that because the intramedullary cavity space of the tibia is very small, if the injection volume is too large, it will overflow from the intramedullary cavity of the tibia, and tumor cells will grow outside the tibia to form a tumor, which is not a bone tumor, so the injection volume (preferably ≤12 microliters, more preferably ≤10 microliters) is very important to ensure tumor formation in the tibia.

[0078] Osteosarcoma cells

[0079] The osteosarcoma cells suitable for the method and animal model of the present invention are human osteosarcoma cells, and the osteosarcoma cells include primary osteosarcoma cells and passaged osteosarcoma cells.

[0080] The inventors have found through screening that certain specific human osteosarcoma cells are particularly suitable for forming osteosarcoma lesions in situ and lung metastasis in mice. Representative osteosarcoma cells are selected from the following group: 143B cells, MNNG cells, MG-63 cells, U-2OS cells, or a combination thereof. A particularly preferred osteosarcoma cell is 143B cells.

[0081] In the present invention, the osteosarcoma cells may be either non-genetically engineered or genetically engineered.

[0082] In another preferred embodiment, the osteosarcoma cells express exogenous marker proteins that can be used for detection.

[0083] In another preferred embodiment, the marker protein is selected from the following group: luciferase, green fluorescent protein (GFP), red fluorescent protein (RFP), yellow fluorescent protein (YFP), or a combination thereof.

[0084] Preferably, the osteosarcoma cells are 143B cells expressing luciferase and / or 143B cells expressing GFP.

[0085] In the present invention, osteosarcoma cells labeled with luciferase or fluorescent protein (such as GFP) are injected into the tibial bone marrow cavity, which can facilitate tracking the growth status of primary and metastatic osteosarcoma.

[0086] Matrigel

[0087] Matrigel is a basement membrane matrix derived from EHS mouse sarcoma, which contains about 60% laminin, 30% IV collagen and 8% nestin, as well as perlecan, TGF-β, epidermal growth factor, insulin-like growth factor, tissue plasminogen and other growth factors.

[0088] In the present invention, a particularly preferred type is standard Matrigel, wherein the concentration of the matrix component ranges from about 6 to 15 mg / ml, preferably 8 to 12 mg / ml.

[0089] The inventors unexpectedly discovered that the use of Matrigel to resuspend osteosarcoma cell pellets to prepare a modeling injection solution can be more conducive to the formation of a microenvironment in the mouse tibial bone marrow cavity that is conducive to the survival and growth of osteosarcoma cells, and osteosarcoma lesions with lung metastasis can be obtained in a very short time (only 3-4 weeks).

[0090] Mechanistic studies and candidate drugs or therapeutic agents

[0091] The present invention also provides a use of the animal model of the present invention, including (but not limited to): mechanism research, and a method for screening candidate drugs or therapeutic agents for treating osteosarcoma and its related lung metastasis.

[0092] In the present invention, candidate drugs or therapeutic agents refer to substances that are known to have certain pharmacological activities or are being tested and may have certain pharmacological activities, including but not limited to: nucleic acids, proteins, carbohydrates, chemically synthesized small molecules or macromolecular compounds, cells, etc. The administration of candidate drugs or therapeutic agents can be oral, intravenous, intratumoral, intraperitoneal, subcutaneous, etc.

[0093] The main advantages of the present invention include:

[0094] (a) The mouse model of the present invention has the characteristics of short incubation period and fast growth. Usually, osteosarcoma in the tibia can be observed in 2 weeks, and lung metastasis can be observed in 3 weeks.

[0095] (b) The mouse model of the present invention has the characteristics of severe osteosarcoma lesions and sensitive growth monitoring of primary lesions and lung metastatic lesions.

[0096] (c) In the method of the present invention, tumor cells in a conventional 10 cm culture dish can be used to prepare about 10 or more model mice in one batch, and the differences in osteosarcoma lesions and lung metastasis lesions among the model mice are small, which is helpful for pathological research and drug screening.

[0097] In summary, the mouse model of the present invention is an ideal model for exploring the role and mechanism of specific factors in the pathological process of osteosarcoma. It is also an ideal tool for studying lung metastasis, tumor microenvironment and evaluating the therapeutic effect in vivo.

[0098] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise indicated, percentages and parts are weight percentages and weight parts.

[0099] Unless otherwise specified, the reagents and materials used in the present invention are commercially available or can be prepared according to literature methods. Experimental reagents and methods not specifically specified are conventional reagents and methods.

[0100] The Matrigel used in the examples is a commercially available product, wherein the concentration of the matrix component ranges from about 8 to 12 mg / ml.

[0101] Example 1 Preparation of model animals

[0102] 1. Experimental steps

[0103] The animal experiments were approved by the Animal Welfare Committee of Shanghai University of Traditional Chinese Medicine.

[0104] 1. Cell Preparation

[0105] 1.1 On the day of injection of osteosarcoma cells (143B), 143B osteosarcoma cells (the 143B cells have been genetically engineered and a luciferase expression cassette has been integrated into the genome to express exogenous luciferase) in a 10 cm cell culture dish with good growth and about 80% confluence were washed twice with PBS (pH 7.4), and then digested with 1.5 ml of 0.25% trypsin at 37 degrees Celsius for 3-5 minutes. After adding 6 ml of MEM medium containing 10% serum to terminate the digestion, the cells were collected in a 15 ml centrifuge tube.

[0106] 1.2 Count cells using an automatic cell counter and calculate the cell concentration (the total number of tumor cells is about 3×10 6 cells).

[0107] 1.3 Centrifuge the cells at 800 g for 5 minutes at room temperature.

[0108] 1.4 Aspirate and discard the supernatant, and resuspend the cell pellet with Matrigel to a final concentration of 2×10 4 cells / μl.

[0109] 1.5 Place the cell preparation mixed with Matrigel (i.e., the injectable composition for modeling) on ​​ice until use, and use it within the shortest possible time (no more than 2 hours).

[0110] 1.6 Transfer the cell preparation on ice to the operating room for later use.

[0111] 2. In situ injection of osteosarcoma cells

[0112] 2.1 Tools required for surgery such as Figure 1 shown.

[0113] 2.2 Ensure that the mice have no special lesions, and all operations during the modeling process must be sterile.

[0114] 2.3 The entire surgical procedure should be performed under anesthesia in a well-ventilated area, using 2% isoflurane and 98% oxygen for anesthesia.

[0115] 2.4 The mouse is kept in a supine position. The operator holds the mouse ankle joint with the thumb and index finger at the same time and disinfects the tibia injection site with a 75% alcohol swab. Note: It is very important to hold the mouse ankle joint tightly with the thumb and index finger tips for subsequent operations.

[0116] 2.5 The ankle joint of the mouse is externally rotated to mobilize the tibia and fibula, and the knee joint is flexed to a suitable position until the proximal tibial plateau (top of the tibia) can be clearly seen through the skin ( Figure 2 A).

[0117] 2.6 Use a 1 ml syringe needle, point the needle tip to the injection site and ensure that the syringe needle is parallel to the long axis of the tibia. Insert the needle through the knee joint to the distal tibia percutaneously until the needle tip reaches the center of the tibial plateau surface. Then rotate the syringe (1 / 2 to 3 / 4 turn) to drill a hole through the tibial plateau to the distal tibia (medullary cavity) for subsequent injection of osteosarcoma cells into the tibial medullary cavity using a microsyringe ( Figure 2 B, 2C). Note: If the needle tip is positioned correctly, you will feel the needle rotating as you drill. Make sure the needle moves with the rotation of the syringe, rather than pushing straight forward, until about half of the needle is inside the tibial medullary cavity.

[0118] 2.7 A noticeable feeling of the needle tip falling into the air indicates that the drilling is successful.

[0119] 2.8 Perform an X-ray to confirm the correct needle placement and obtain an image.

[0120] 2.9 The prepared 143B osteosarcoma cell suspension (i.e., the injectable composition for modeling) was placed into a microsyringe, and the needle of the microsyringe was inserted into the tibial medullary cavity of the mouse along the hole drilled in item 2.6 ( Figure 2 D). Then 10 μl of 143B cell suspension (about 2×10 5 cells) were slowly injected into the tibia bone marrow of immunodeficient nude mice.

[0121] 2.10 After removing the microsyringe, press the injection site with a cotton swab for 20-30 seconds.

[0122] 2.11 Place the mouse back into a clean cage and monitor closely until it has fully recovered from anesthesia.

[0123] 2.12 X-ray imaging system was used to monitor tumor growth in vivo. The longest diameter (a) and shortest diameter (b) of the in situ osteosarcoma mass were measured with a vernier caliper every week, and the tumor volume (V) was calculated as follows: V = 1 / 2 × a × b 2 .

[0124] 3. Pathological examination (collecting in situ / primary and lung metastatic osteosarcoma specimens for analysis)

[0125] 3.1 Six weeks after osteosarcoma cell injection, mice were killed by cervical dislocation under CO2 inhalation.

[0126] 3.2 Keep the mouse in supine position with both hind limbs extended.

[0127] 3.3 The entire hind limb (tibia and femur) affected by osteosarcoma was dissected from the groin to ensure that the affected hind limbs of each mouse were separated from the same anatomical position. After removing the skin, muscles and feet, they were fixed in 50 ml centrifuge tubes containing 20 ml formalin solution for 24 hours (1 mouse / tube), and then transferred to 10% EDTA decalcification solution for decalcification for 14 days. The decalcification solution was changed every 3 days. The decalcified specimens were used for freezing or paraffin embedding.

[0128] 3.4 The whole lung tissue was separated and fixed in a 50 ml centrifuge tube containing 20 ml formalin solution for 24 hours (1 piece / tube), then transferred to a 15 ml centrifuge tube containing 75% ethanol (1 piece / tube), embedded in paraffin, and used for HE staining and immunohistochemistry.

[0129] 2. Results

[0130] The successful establishment of orthotopic (primary) osteosarcoma and lung metastasis models depends on the precise orthotopic injection of osteosarcoma cells. In this example, an orthotopic (primary) osteosarcoma model was successfully established in 9 immunodeficient nude mice by intramedullary injection of osteosarcoma cells into the tibia.

[0131] Figure 3A is a representative orthotopic osteosarcoma mouse model. Figure 3 B is a representative orthotopic osteosarcoma after dissection. Tumor diameter was measured once a week with a vernier caliper, and tumor volume was calculated as described in the experimental procedure ( Figure 3 C).

[0132] The growth of orthotopic osteosarcoma in vivo can be tracked by X-ray and bioluminescence (e.g., by injecting osteosarcoma cells labeled with luciferase) live imaging systems. Figure 3 D shows X-ray images from week 1 to week 6 after 143B osteosarcoma cell injection. Figure 3 E is an image of in situ (primary) osteosarcoma growth in vivo obtained after luciferase-labeled 143B cells were injected into the tibial bone marrow of mice. Figure 4 As shown in A, the bioluminescent in vivo imaging system can track lung metastasis caused by intramedullary injection of luciferase-labeled osteosarcoma cells into the tibia. Metastatic clones can also be seen in dissected lung tissue under a stereomicroscope ( Figure 4 B), and metastatic lesions were further confirmed by H&E staining of paraffin-embedded lung tissue ( Figure 4 C).

[0133] Comparative Example C1

[0134] The method of Example 1 was repeated, except that in step 1.4, the cell pellet was resuspended in MEM medium to a final concentration of 2×10 4 cells / μl.

[0135] Results: As shown in Table 1, the mouse models of orthotopic osteosarcoma and lung metastasis could not be effectively established when MEM medium was used.

[0136] Comparative Example C2

[0137] The method of Example 1 was repeated, except that in step 1.4, the cell pellet was resuspended in MEM medium to a final concentration of 4×10 4 cells / μl, and then matrigel was added at a 1:1 volume ratio to obtain a final concentration of 2×10 4 cells / μl mixture.

[0138] Results: As shown in Table 1, although a mouse model of osteosarcoma and lung metastasis can be established, it takes a long time (lung metastasis can only be observed after 6-8 weeks), and the size of the in situ osteosarcoma tumor is small (about 50%-55% of that in Example 1).

[0139] Some experimental results of Example 1 and Comparative Examples C1 and C2 are listed in Table 1 below.

[0140] Table 1

[0141]

[0142] Example 2

[0143] The method of Example 1 was repeated, except that osteosarcoma cells Saos-2, MNNG, MG-63, U-2OS, and other types of 143B cells were used to replace the luciferase-expressing osteosarcoma cells 143B in Example 1.

[0144] result

[0145] As shown in Table 2, the in situ osteosarcoma tumor formation rate of Saos-2 cells was 20%, and the lung metastasis rate was 10%, the in situ and lung metastasis tumor formation rates of U-2OS cells were 80%, while the in situ and lung metastasis tumor formation rates of MNNG cells, MG-63 cells and 143B cells were 100%, especially the lung metastasis tumor formation time of 143B cells (three marker types) was the shortest.

[0146] The mouse model of osteosarcoma and lung metastasis was prepared using 143B cells expressing exogenous GFP. The growth of orthotopic osteosarcoma and lung metastasis in vivo can be observed under a fluorescence microscope after dissection. Figure 5 A shows a paraffin-embedded section of an in situ osteosarcoma specimen obtained under a microscope; Figure 5 B shows a whole-body image of an osteosarcoma lung metastasis specimen obtained under a fluorescence microscope.

[0147] Table 2

[0148]

[0149] discuss

[0150] Osteosarcoma is the most common primary bone tumor in children and adolescents, and the lungs are the most common site of osteosarcoma metastasis. The five-year survival rate of osteosarcoma patients with lung metastasis is less than 30%. Therefore, the use of a mouse model that best simulates the progression of clinical osteosarcoma patients and lung metastasis is of great significance for a deeper understanding of the mechanisms of osteosarcoma lesions and lung metastasis and the development of new treatments.

[0151] The primary osteosarcoma model prepared by in situ injection of osteosarcoma cells is an ideal model to study the role and mechanism of specific factors in the development of primary osteosarcoma and to evaluate the therapeutic effects of different intervention factors. Care should be taken to inject the same number of osteosarcoma cells in the most active state into the tibial medullary cavity of each mouse to avoid differences in tumor growth. Therefore, the time of digestion of cells with trypsin should be strictly controlled without affecting the viability of cells. Since cell clumps affect cell counts, resulting in inaccurate numbers of cells injected into the tibial medullary cavity of each mouse, the cell suspension needs to be fully resuspended and evenly suspended to avoid the formation of cell clumps.

[0152] Another important aspect that should be considered is the solution used to resuspend osteosarcoma cells. The inventors have shown that the injected cells used for modeling should be resuspended in matrigel, rather than in PBS or culture medium. In addition, high concentrations of matrigel will affect the injection volume and make it difficult to pipette, so the concentration of matrigel is best with 8-12 mg / ml of matrix components.

[0153] When drilling a hole in the tibial plateau for osteosarcoma cell injection, the syringe needle should move forward with the rotation of the syringe, rather than pushing forward directly, until about half of the needle enters the tibial medullary cavity. In addition, when injecting osteosarcoma cells, if a conventional syringe (such as a 1 ml graduated syringe) is used, the error is too large due to the large scale and the dead space often exists in the syringe, resulting in very inaccurate injection dosage. For this reason, the method of the present invention uses a micro-syringe to more accurately inject a quantitative injectable composition for modeling.

[0154] The choice of osteosarcoma cell line determines the success of the in situ and lung metastasis osteosarcoma model. The inventors found that 143B, MNNG, MG-63 and U-2OS cells have higher tumorigenicity than Saos-2 cells, especially 143B and MNNG are preferred osteosarcoma cells.

[0155] More importantly, to make an orthotopic osteosarcoma model with human osteosarcoma cells, immunodeficient mice should be selected. At the same time, the injection process should be performed in a biosafety cabinet and autoclaved surgical instruments should be used. Because surgery and anesthesia may cause discomfort to mice, the first week after surgery is very critical and the physiological state of the mice needs to be closely monitored. The injected osteosarcoma cells can also be labeled with fluorescent proteins or luciferases, so that primary lesions and metastatic lesions can be tracked and observed with a live imaging system. The volume of osteosarcoma is not allowed to exceed the size limit approved by IACC. At the same time, if the tumor volume is too large, ulcers may occur, leading to failure of analysis such as immunohistochemistry.

[0156] In conclusion, this orthotopic (primary) osteosarcoma and lung metastasis model prepared by intramedullary injection of osteosarcoma cells into the tibial bone marrow cavity is a very useful tool for studying the tumor microenvironment and the effects of therapeutic approaches on osteosarcoma growth and / or metastasis. In addition, by intramedullary injection of transgenic osteosarcoma cells targeting a certain gene, this model helps to explore the role of key oncogenes and tumor suppressor factors in osteosarcoma growth and lung metastasis.

[0157] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.

[0158] Literature

[0159] 1. Bielack, S.S., et al., Prognostic factors in high-grade osteosarcoma of the extremities or trunk: an analysis of 1,702 patients treated on neoadjuvant cooperative osteosarcoma study group protocols. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 2002. 20(3): p. 776-790.

[0160] 2. Yang, C., et al., Bone Microenvironment and Osteosarcoma Metastasis. International journal of molecular sciences, 2020. 21(19).

[0161] 3. Mirabello, L., R.J. Troisi, and S.A. Savage, Osteosarcoma incidence and survival rates from 1973 to 2004: data from the Surveillance, Epidemiology, and End Results Program. Cancer, 2009. 115(7): p. 1531-1543.

[0162] 4. Tsukamoto, S., et al., Current Treatment Considerations for Osteosarcoma Metastatic at Presentation. Orthopedics, 2020. 43(5): p. e345-e358.

[0163] 5.Zhang,B.,et al.,The efficacy and safety comparison of first-linechemotherapeutic agents(high-dose methotrexate,doxorubicin,cisplatin,andifosfamide)for osteosarcoma:a networkmeta-analysis.Journal of orthopaedicsurgery and research,2020.15(1):p.51.

[0164] 6.Sharma,S.,et al.,Osteosarcoma of the proximal tibia in a dog 6years after tibial tuberosity advancement.The Canadian veterinary journal=Larevue veterinaire canadienne,2020.61(9):p.946-950.

[0165] 7.Leacock,S.W.,et al.,A zebrafish transgenic model of Ewing's sarcomareveals conserved mediators of EWS-FLI1 tumorigenesis.Disease models&mechanisms,2012.5(1).

[0166] 8.Castillo-Tandazo,W.,A.J.Mutsaers,and C.R.Walkley,Osteosarcoma inthe Post Genome Era:Preclinical Models and Approaches to Identify TractableTherapeutic Targets.Current osteoporosis reports,2019.17(5):p.343-352.

[0167] 9.Mason,N.J.,Comparative Immunology and Immunotherapy of CanineOsteosarcoma.Advances in experimental medicine and biology,2020.1258:p.199-221.

[0168] 10.Cobb,L.M.,Radiation-induced osteosarcoma in the rat as a model forosteosarcoma in man.British journal of cancer,1970.24(2):p.294-299.

[0169] 11.Walkley,C.R.,et al.,Conditional mouse osteosarcoma,dependent onp53 loss and potentiated by loss of Rb,mimics the human disease.Genes&development,2008.22(12):p.1662-1676.

[0170] 12.Entz-Werlé,N.,et al.,Targeted apc;twist double-mutant mice:a newmodel of spontaneous osteosarcoma that mimics the human disease.Translationaloncology,2010.3(6):p.344-353.

[0171] 13.Chang,J.,et al.,MicroRNAs for osteosarcoma in the mouse:a meta-analysis.Oncotarget,2016.7(51):p.85650-85674.

Claims

1. Use of an injectable modeling composition, characterized in that, Used to prepare a mouse animal model of osteosarcoma and lung metastasis; wherein the volume of the modeling composition is 8-15 μl, the modeling composition is a suspension composed of Matrigel and osteosarcoma cells, wherein the total number of human osteosarcoma cells in the modeling composition is 1×10 5 Up to 3×10 5 ; And, the osteosarcoma cells are selected from the group consisting of MG-63 cells, MNNG cells, or a combination thereof.

2. The use according to claim 1, characterized in that The modeling composition is formed by resuspending and centrifuging osteosarcoma cell sediments obtained by Matrigel.

3. The use according to claim 1, characterized in that The concentration of human osteosarcoma cells in the modeling composition is 1×10 4 Up to 3×10 4 / μl.

4. The use according to claim 1, characterized in that The concentration of human osteosarcoma cells in the modeling composition is 1.5×10 5 Up to 2.5×10 4 / μl.

5. The use according to claim 1, characterized in that The concentration of human osteosarcoma cells in the modeling composition is 1.8×10 4 to 2.2×10 4 / μl.

6. The use according to claim 1, characterized in that The osteosarcoma cells include primary osteosarcoma cells and passaged osteosarcoma cells.

7. The use according to claim 1, characterized in that The osteosarcoma cells are MNNG cells or MG-63 cells.

8. The use according to claim 1, characterized in that In the injectable modeling composition, the concentration range of the Matrigel matrix component is 6-15 mg / ml.

9. The use according to claim 1, characterized in that In the injectable modeling composition, the concentration range of the Matrigel matrix component is 8-12 mg / ml.

10. The use according to claim 1, characterized in that The mouse animal model of osteosarcoma and lung metastasis has one or more characteristics selected from the following group: (c1) osteosarcoma in situ in the tibia more than 2 weeks after modeling; (c2) osteosarcoma with lung metastasis in the lungs more than 3 weeks after modeling; (c3) At 4 weeks after modeling, the volume of the osteosarcoma in situ in the tibia was ≥500 mm 3 ; (c4) At 5 weeks after modeling, the volume of the osteosarcoma in situ in the tibia was ≥800 mm 3 ; (c5) Six weeks after modeling, the volume of the osteosarcoma in situ in the tibia was ≥1000mm 3 .

11. The use according to claim 10, characterized in that At 4 weeks after modeling, the volume of the orthotopic osteosarcoma in the tibia was ≥ 600 mm 3 .

12. The use according to claim 10, characterized in that At 4 weeks after modeling, the volume of the orthotopic osteosarcoma in the tibia was ≥700 mm 3 .

13. The use according to claim 10, characterized in that At 5 weeks after modeling, the volume of the orthotopic osteosarcoma in the tibia was ≥900 mm 3 .

14. The use according to claim 10, characterized in that At 5 weeks after modeling, the volume of the orthotopic osteosarcoma in the tibia was ≥1000mm 3 .

15. The use according to claim 10, characterized in that At 6 weeks after modeling, the volume of the orthotopic osteosarcoma in the tibia was ≥1100mm 3 .

16. The use according to claim 10, characterized in that At 6 weeks after modeling, the volume of the orthotopic osteosarcoma in the tibia was ≥1200mm 3 .

17. Use of the mouse animal model of osteosarcoma and lung metastasis as claimed in claim 1, characterized in that: The model is used as an animal model for studying the pathogenesis of human osteosarcoma, or as an animal model for screening potential drugs for treating human osteosarcoma.

18. The use according to claim 17, characterized in that The potential drug inhibits the growth of osteosarcoma in situ and inhibits the lung metastasis of osteosarcoma.

19. A non-diagnostic and non-therapeutic method for screening potential therapeutic agents for the treatment of osteosarcoma and its associated lung metastases, comprising the following steps: (a) in a test group, a test compound is administered to the mouse animal model of claim 1 in the presence of the test compound, and the osteosarcoma lesions in the tibia and / or the osteosarcoma lesions of lung metastasis in the animal model of the test group are analyzed, and in a control group in which the test compound is not administered and other conditions are the same, the osteosarcoma lesions in the tibia and / or the osteosarcoma lesions of lung metastasis in the animal model of the control group are analyzed; (b) comparing the lesions of the test group and the control group animal models, wherein, if the lesions in the animal model administered with the test compound are improved compared with the control group, it indicates that the test compound can be used as a potential therapeutic agent for osteosarcoma and its related lung metastasis.

20. A kit for preparing a mouse animal model of osteosarcoma and lung metastasis, characterized in that: The kit includes: (Z1) an injectable modeling composition, wherein the volume of the modeling composition is 8-15 μl, and the modeling composition is a suspension consisting of Matrigel and osteosarcoma cells, wherein the total number of human osteosarcoma cells in the modeling composition is 1×10 5 Up to 3×10 5 ; And, the osteosarcoma cells are selected from the group consisting of MG-63 cells, MNNG cells, or a combination thereof; (Z2) a microsyringe, wherein the microsyringe is configured to administer 8-15 microliters of the injectable modeling composition to the tibia of a mouse; (Z3) a 1 ml graduated syringe, wherein the 1 ml graduated syringe is configured to form a modeling microhole on the tibia of the mouse, wherein the modeling microhole is suitable for the microsyringe to perform modeling injection; (Z4) Optional luciferase substrate.

21. Use of the kit according to claim 20, characterized in that Used to prepare a kit, which is used to prepare a mouse animal model of osteosarcoma and lung metastasis.